The Ministry of Industry and Information Technology urges the development of the pharmaceutical industry

On September 23, it was learned from the website of the Ministry of Industry and Information Technology that in order to further implement the “China Manufacturing 2025” work plan and promote the sustained and healthy development of the pharmaceutical industry, according to the 1+X planning work requirements, on the 21st, the Consumer Products Industry Department of the Ministry of Industry and Information Technology was organized in Beijing. "Thirteenth Five-Year Plan for the Development of Pharmaceutical Industry" preparation work conference.

Xin Guobin, deputy minister of the Ministry of Industry and Information Technology, pointed out that in the past two years, China's pharmaceutical industry has maintained a medium- and high-speed growth, ranking among the top ranks in various industrial categories, and the profit rate is significantly higher than that of the industry as a whole. However, there are still problems in the development of the industry, such as the need to improve the innovation system, the urgent need to upgrade the product structure, and the need to improve quality and safety. Through the preparation of the plan, the top-level design and scientific planning for the development of China's pharmaceutical industry will be of great significance for guiding the healthy and sustainable development of the pharmaceutical industry. Xin Guobin requested that firstly, integrate the development of the pharmaceutical industry into the overall strategy for the construction of a strong manufacturing country, consider the connection with "Made in China 2025," and strengthen the scientific decision-making, give full play to the role of the expert committee, and support the expert advisory committee to play well. The role of decision-making consulting, industry leadership, and investigation and research ensures that the planning is scientific and authoritative. Third, it strengthens communication and cooperation, and cooperates with relevant departments to achieve good convergence with other related departmental policies, and promotes the healthy development of the pharmaceutical industry. Together force.

As the director of the Expert Consultation Committee for the preparation of this plan, Academician Sang Guowei pointed out in his speech that the preparation of the "13th Five-Year Plan for the Development of the Pharmaceutical Industry" must incorporate the spirit of innovation-driven development; it must be consistent with the requirements for deepening medical reform. , to meet the people's health needs as the direction; to promote industrial restructuring and optimize the industrial layout and make more efforts; to strengthen the linkage between departments, starting from the top level design, taking into account the various aspects of the industrial chain, identify the policy force, so that Decisions of all relevant departments form a joint force to jointly promote the healthy development of the pharmaceutical industry.

The meeting determined that experts from various fields in the pharmaceutical industry and experts from major industry associations, key enterprises, pharmaceutical universities, scientific research institutions, and professional organizations will form an expert advisory committee to give guidance on the planning. The 13th Five-year Development Plan for the Pharmaceutical Industry will be jointly prepared and released by the Ministry of Industry and Information Technology, the Development and Reform Commission, the Ministry of Commerce, the Health and Family Planning Commission and the Food and Drug Administration.

Previous media reports that biopharmaceuticals and medical devices will be the two major breakthroughs for the preparation of the 13th Five-Year Plan for pharmaceuticals. Haitong Securities believes that medical device companies face historic opportunities for industrial restructuring and related departments or introduce more policies to support high-performance medical services. With the development of devices and the enthusiasm for the innovation of medical device companies, the value of relevant concept stocks is expected to be further re-evaluated. A shares of Haiwang Bio, Lepu Medical and other listed companies involved in biomedical and medical equipment and other related businesses.